← Return to Aromatase Inhibitors: Did you decide to go on them or not?

Discussion

Aromatase Inhibitors: Did you decide to go on them or not?

Breast Cancer | Last Active: May 12, 2023 | Replies (1190)
Comment receiving replies
@callalloo

Good. I was referring to any genetic test but the test I had was the OncotypeDX. The customer service reps are great and, when I had a question they couldn't be absolutely sure about, I was able to talk to someone in the science side of the firm. He answered a question, about which both my o cologist and ontological radiologist were flat out incorrect (sic) and put the answer in writing. I took his email to them and the vreast cancer surgeon because they were, well wrong, and needed to advise patients correctly. [My PCP congratulated me for persistence in double-checking, as did a consulting endocrinologist, and I had the letter entered into my medical file.]

Jump to this post

Replies to "Good. I was referring to any genetic test but the test I had was the OncotypeDX...."
jaynep | @jaynep | Apr 16, 2022

Do you mind telling what they were wrong about?

VIEW AND REPLY
windyshores | @windyshores | Apr 16, 2022

Here is the excerpted text from breastcancer.org:

For invasive:
"So, the Oncotype DX Breast Recurrence Score Test is both a prognostic test, since it provides more information about how likely (or unlikely) the breast cancer is to come back, and a predictive test, since it predicts the likelihood of benefit from chemotherapy or radiation therapy treatment. Studies have shown that Oncotype DX Breast Recurrence Score Test is useful for both purposes."
For DCIS:
(After the Oncotype) "Radiation therapy may be recommended for some women. Doctors aren’t always sure which women will benefit from radiation therapy."

I was surprised. Back in 2014 Radiation was not mentioned in the context of the Oncotype, only pathology. @callalloo are you saying this is mistaken?

VIEW AND REPLY